Liquidia (LQDA) Stock Price & Analysis
Score
AI Analysis
SnapshotLiquidia is a growth-led story right now — Growth 88/100 is the pillar doing the heavy lifting (overall 72/100) in Medical - Pharmaceuticals. Under the hood: P/E 28.3, plus revenue compounding ~340% annually over recent years. Street targets still imply ~26% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Liquidia Corporation (LQDA) last printed $57.41. Equity value is $5.17B. Trailing earnings multiple 36.82. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $13.22M | $7.26M | $2.71M | $8.07M | $739,628.00 | $12.85M | $15.94M | $17.49M | $14M | $158.32M |
About
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.